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Vitamin A Modulation ofXenobiotic-induced
Hepatotoxicity in Rodents
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Vitamin A (VA, retinol) has been shown to modulate cells of the immune system. When rats are pretreated with VA (75 mg/kg/day) for 7 days, there
is greatly potentiated liver damage upon subsequent exposure to hepatotoxicants such as CC14. This potentiated damage can be blocked by superox-
ide dismutase or catalase, suggesting that reactive oxygen species are playing a major role in the increased liver injury. The studies reported here
examined VA-induced modulation of CCI4 hepatotoxicity in different strains of male rats, female rats, and different strains of male mice. Also, the role
of VA-induced weight loss on potentiation of CCI4 injury was investigated. Rats or mice were dosed with VA (retinol) at 75 mg/kg/day, po, for 7 days.
In an additional VA dose-response study, mice were given VA at 18.8, 37.5, or 75 mg/kg/day, po, for 7 days. On day 8 they were given a dose of
CCI4 which elicited mild hepatic damage. On day 9 they were necropsied. Male and female Sprague-Dawley rats, and male Fischer-344 and athymic
nude rats pretreated with VA had an approximately 10-fold increase in liver damage as compared to vehicle controls. Pretreatment of male Balb/C,
C3H/HeJ, Swiss-Webster, or athymic nude mice resulted in a marked reduction of CCI4-induced hepatic damage. In the dose-response study in
mice, increasing doses of VA elicited increasing amounts of protection from CCI4-induced liver injury. Paired feeding studies revealed that VA-induced
weight loss (or decreased weight gain) had no effect on subsequent VA-induced potentiation (rats) or protection (mice) from hepatic damage caused
by CC)4. These results indicate that VA-induced potentiation of CCI4 hepatotoxicity is similar in male and female Sprague-Dawley rats and in male T-
lymphocyte-deficient nude rats. However, in mice, VA pretreatment results in protection from CCI4-induced liver injury. The results also show that
the VA associated weight loss has no effect on modulation of hepatic injury in rats or mice.-Environ Health Perspect 102(Suppl 9):39-43(1994)
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Introduction
Many chemicals, such as carbon tetrachlo-
ride, allyl alcohol, and acetaminophen are
known to cause liver damage upon expo-
sure. Likewise, numerous compounds, such
as vitamin A (retinol), endotoxin (lipopoly-
saccharide), and methyl palmitate have
been demonstrated to modulate the func-
tion of the immune system after their
administration (1,2). Little is known,
however, about the role ofthe immune sys-
tem in the progression ofliver damage and
even less well characterized are the effects
of immune system modulators on xenobi-
otic-induced hepatotoxicity.
Kupffer cells [(KC), resident macro-
phages of the liver] and neutrophils poly-
morphonuclear (PMN) are phagocytic
white blood cells that have recently been
shown to play a role in liver injury (3-5).
Studies suggest that the contribution ofKC
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or PMN to liver injury varies depending on
the hepatotoxic agent. Regardless ofwhich
type ofwhite blood cell is involved, release
of cytotoxic factors are responsible for
increased hepatocellular damage. Examples
of cytotoxic factors are reactive species of
oxygen (ROS) such as superoxide anion
and nitric oxide, and proteases (6,7).
Presumably, when hepatocytes or hepatic
nonparenchymal cells (NPC) are damaged,
chemical mediators are released which
stimulate KC and PMN to release ROS
and proteases resulting in increased injury
to surrounding hepatocytes and NPC.
Therefore, immunomodulators could affect
KC and PMN in one oftwo ways; either to
suppress their function resulting in
decreased hepatic damage or to increase
their function, causing increased or poten-
tiated damage. Experiments in this labora-
tory have been principally focused on
vitamin A-induced modulation of hepato-
toxicity caused byxenobiotic compounds.
Vitamin A (VA, retinol) is found in
many foods and is available as an over-the-
counter food supplement. Besides its
requirement for normal cellular function, it
has been shown to be beneficial as an
adjunct to cancer chemotherapy and in the
prevention of some types of skin cancer.
Among its physiological effects, VA (as
retinol or retinoic acid) can activate
macrophages in vivoand in vitro (2,8).
Original investigations in this labora-
tory sought to determine the consequences
of high doses of VA on the subsequent
exposure to a hepatotoxicant such as car-
bon tetrachloride (CC14). It was discovered
that the administration of VA (retinol) by
oral gavage to male Sprague-Dawley rats at
a dose of 75 mg/kg/day for 7 days, greatly
potentiated the hepatotoxicity of a subse-
quent ip dose of CC14 as determined by
increased plasma ALT activity and
increased histologic hepatic damage (9). In
a VA dose-response study in rats, increas-
ing doses ofVA from 30 to 75 mg/kg/day,
po, for 7 days, elicited increasing potentia-
tion of CC)4-induced liver injury (10).
Administration of superoxide dismutase
(SOD) or catalase eliminated the potenti-
ated damage, implicating release ofROS by
KC as the cause of the increased damage
(9). In addition, when KC isolated from
VA-pretreated rats were stimulated in vitro,
they produced significantly greater
amounts of superoxide anion as compared
to KC from controls (11). However, it was
noted that VA-treated rats had reduced
weight gain or lost weight during the treat-
ment period, while the corn oil controls
had a gain in bodyweight ofapproximately
20% during the treatment period. Since
the preceeding experiments were only per-
formed in male Sprague-Dawley rats and
because of concern about weight loss in
VA-treated animals, the following experi-
ments were designed to answer three ques-
tions. First, do other strains ofrats, and do
female rats exhibit the same VA-induced
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Table 1. Plasma ALTactivities in athymic nude, male and female Sprague-Dawley, and F-344 rats.
Treatment PlasmaILTActivities ( mean ± SE)
groupa Male Nude Male Sprague-Dawley Female Sprague-Dawley Male Fischer-344
Veh/Veh 36±1 (n=3) 28±2 (n=2) 31 ±4 (n=2) 26±4 ' (n=4)
VA/Veh 36±2 (n=3) 32±4 (n=2) 46 (n=1) 17±1 (n=4)
Veh/CCI4 734 ±79 (n=3) 221 ±40 (n=4) 752±286 (n=4) 366± 58 (n=4)
VA/CCI4 5341 ± 1219* (n=3) 2746±293* (n=4) 8351*± 1874 (n=4) 4024*±284 (n=4)
aPretreated with VA(75 mg/kg/day, po) for7 days followed byCCI4(0.2 ml/kg or 0.1 ml/kg[F-344], ip).*,Significantly differentfromVeh/CCI4 group atp<0.05.
potentiation ofCCI4 hepatotoxicity as male
Sprague-Dawley rats? Second, would
another species of laboratory animal (i.e.,
the mouse), have increased hepatotoxicity
with VA pretreatment? Third, does the
decrease in body weight ofVA-treated ani-
mals contribute to the increased hepatotox-
icity present in CCl4-treated animals?
Materials and Methods
All animals were obtained from Harlan
Sprague-Dawley, Inc. (Indianapolis, IN).
They were housed in polycarbonate cages
with hardwood bedding in an AALAC-
approved facility and allowed to acclimate
for at least 1 week before use. They were
given free access to food (Teklad, Harlan
Inc., Indianapolis, IN) and tap water and
were maintained on a 12-hr light-dark cycle.
Rats used in these studies were male Fischer-
344 (F-344), male athymic nudes (rnu from
hooded stock) and male and female Sprague-
Dawley. Males weighed 250 to 350 g and
females 225 to 275 g before the start ofdos-
ing. Mice were male, Swiss-Webster,
B6C3F1, Balb/C, C3H/HeJ (endotoxin
insensitive), and athymic nudes (nu from
albino stock) weighingapproximately25 g.
Aquasol A Drops (retinol, Astra
Pharmaceutical Products, Westborough,
MA) or its vehicle (10% propylene glycol,
7% Tween 20 in distilled water) or retinol
(Fluka Chemical Co., Ronkonkoma, NY)
dissolved in corn oil (rats in paired-feeding
study) were administered to each animal by
oral gavage at a dosage of75 mg/kg/day. In
a VA dose-response study, male Swiss-
Webster mice were dosed with vehicle or
Aquasol A at 18.8, 37.5, or 75 mg/kg/day,
po. In mice, doses of VA greater than 75
mg/kg/day for 7 days were judged to be too
toxic for evaluation. Rats and mice were
dosed for 7 consecutive days. On day 8 rats
were dosed with corn oil (vehicle) or CCl4
(Aldrich Chemical Co., Milwaukee, WI) at
0.2 ml/kg (nude and Sprague-Dawley) or
0.1 ml/kg (F-344), ip. Because ofthe sensi-
tivity of mice to CC14-induced liver dam-
age, its very steep-dose response in this
species, and due to strain differences, three
different doses ofCCI4, administered by the
ip route, were necessary to obtain compara-
ble degrees of liver injury in these mouse
strains. Therefore, on day 8 Balb/C mice
were dosed with CC14 at 12.5 pl/kg, Swiss-
Webster mice at 20 pIl/kg and C3H/HeJ
and athymic nude mice at 15 pl/kg.
Twenty-four hours after the administration
of CC14, the animals were killed by CO2
inhalation and exsanguinated through the
posterior vena cava. Heparinized blood
samples were immediately collected and
plasma separated for determination ofALT
activities using a Beckman DU-7 spec-
trophotometer (Sigma kit No. 59-20,
Sigma, St. Louis, MO). A section of liver
was fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned at 5 to 6
pm, stained with hematoxylin and eosin
and examined microscopically.
In paired-feeding studies, male Sprague-
Dawley rats (250-300 g) or male Swiss-
Webster mice (25 g) were individually
housed. To ensure that each VA-vehicle
animal ate the same amount as a VA-
treated, the amount of rodent-chow eaten
by each VA-treated animal was weighed
daily, and the same percentage offood per
gram body weight was given to its pair-fed
VA-vehicle control animal the next day.
With regard to VA and CCd4 dosing, and
necropsy procedures, these animals were
treated identically to those above.
A
B
Figure 1. Photomicrographs of livers from male
Sprague-Dawley rats pretreated with vitamin A (75
mg/kg/day, po) for 7 days. On day 8, they were treated
with CCI4(0.2 ml/kg). Necropsies were performed on day
9. H&E x 33.(A)Veh/CCI4: there is severe vacuolization,
enlargement, and necrosis of hepatocytes adjacent to
the central vein. (B) VA/CCI4: there is vacuolization,
enlargement and degeneration of midzonal hepatocytes
and severe necrosis ofcentrilobularhepatocytes.
Table 2. Plasma ALTactivities in male Balb/C, C3H/HeJ, athymic nude, and Swiss-Webster mice pretreated with Vitamin Afollowed byCCI4 treatment.
Plasma ALT activities (mean ± SE)
Group Balb/C 1C3H/HeJ Athymic nude Swiss-Webster
Veh/Veh 15±2 (n=5) 15±1 (n=3) 17±1 (n=3) 34±7 (n=5)
VA/Veh 20±4 (n=5) 30±3 (n=3) 24±12 (n=3) 20±7 (n=5)
Veh/CCI4 7777* ±2468 (n= 5) 1081 ±834 (n=6) 2134* ±1074 (n=6) 2177* ±480 (n=9)
VA/CC4 1992±1374 (n=5) 124±65 (n=6) 52±11 (n=6) 520±233 (n=9)
Pretreated with VA (75 mg/kg/day, po) for 7 days followed by CCI4. Carbon tetrachloride doses: Balb/C =0.0125 ml/kg, ip; Swiss-Webster = 0.02 ml/kg, ip; C3H/HeJ and athymic
nude =0.015 ml/kg, ip; *significantly differentfromVA/CC14 group atp<0.05.
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Statistical evaluation was performed
using a one-way analysis of variance
(ANOVA) ofthe Number Cruncher Statis-
tical System (NCSS).
Results
Pretreatment ofmale F-344, athymic nude,
and male and female Sprague-Dawley rats
for 7 days with VA (75 mg/kg/day, po)
resulted in potentiation of hepatic damage
as determined by increased plasma ALT
activities and histological examination of
their livers (Table 1). Although CC14 at this
dose (0.2 ml/kg ip) caused greater baseline
toxicity in male athymic nude and female
Sprague-Dawley rats as compared to male
Sprague-Dawley and F-344 rats, VA-pre-
treatment resulted in an approximately
10-foldincrease in CCl4-induced hepato-
toxicity. Histologically, rats treated with
vehicle/CCl4 had mild centrilobufardamage
in the two to four rows ofhepatocytes sur-
rounding the central vein. These cells were
gready enlarged and contained several large,
clear intracytoplasmic vacuoles. Hepatocytes
immediately adjacent to the central vein
were necrotic with shrunken, fragmented
eosinophillic cytoplasm and pyknotic nuclei.
With VA pretreatment, this damage was
more extensive with severe degeneration and
necrosis that included both centrilobular
and midzonal hepatocytes (Figure 1).
Pretreatment of male Swiss-Webster,
Balb/C, C3H/HeJ (macrophage impaired),
and athymic nude mice for 7 days with VA
(75 mg/kg/day, po) resulted in protection
from CCl4-induced hepatic damage as
determined by plasma ALT activities and
microscopic examination of liver sections.
Balb/C and Swiss-Webster mice had an
approximately 4-fold protection, while
C3H/HeJ had approximately 10-fold pro-
tection, and athymic nude mice, a 40-fold
protection (Table 2). The VA dose-
response study in male Swiss-Webster mice
revealed that as the daily dose of VA
increased, from 18.8 to 75 mg/kg/day, the
degree of protection against CCl4-induced
liver injury also increased (Figure 2).
Histologically, mice treated with vehicle/
CCl4 had moderate degeneration and
necrosis of centrilobular hepatocytes
extending to midzonal regions, similar to
that seen in rats. With VA pretreatment,
the centrilobular hepatic damage was much
reduced with minimal hepatocyte damage
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Figure 2 Plasma alanine aminotransferase (ALT) activi-
ties in male Swiss-Webster mice. The mice were
treated bygavage with vehicle orVA at 18.8, 37.5, or 75
mg/kg/day, po, for7 days. On day 8, theywere adminis-
tered CCI4 at 20 pl/kg, ip. Plasma was analyzed for ALT
activity 24 hr following the dose of CCI4. n = 4 for each
VA/CC14 group; n= 14forvehicle/CCI4group.
around the central vein in Swiss-Webster
and Balb/C mice and virtually no hepato-
cyte damage seen in C3H/HeJ or athymic
nude mice (Figure 3).
In the paired feeding study, rats fed ad-
libitum and dosed with VA-vehicle gained
A
(A) Swiss-Webster, Veh/CCI4 0.02 ml/kg. There is (C) C3H/HeJ, Veh/CCI4 0.015 ml/kg. There is severe
severe degeneration and necrosis of centrilobular degeneration and necrosis of centrilobular hepatocytes
hepatocytes. with infiltration of numerous leucocytes.
4i
A .,
B
(B) Swiss-Webster, VA/CC14 0.02 ml/kg. Only a few
hepatocytes immediately adjacent to the central vein
arevacuolated and degenerate.
(E) Athymic Nude, Veh/CCI40.015 ml/kg. Centrilobular
hepatocytes are degenerate with numerous intracyto-
plasmic vacuoles and nuclear pyknosis.
D F
(D) C3H/HeJ, VA/CCI4 0.015 ml/kg. Centrilobular hepa- (F) Athymic Nude, VA/CCI4 0.015 mg/kg. Centrilobular
tocytes appear normal. hepatocytes appear normal.
Figure 3. Photomicrographs of liver from male mice preteated with vitamin A (75 mg/kg/day), po, for 7 days. On day 8 they were treated with CCI4. Necropsies were per-
formed on day 9. H&E x 132
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Table 3. Plasma ALT activities in male Sprague-
Dawley rats pretreated with vitamin A or its vehicle
combined with paired-feeding to one group of vehicle-
treated animals.
Treatment Weight gain, Plasma ALT
group g activities, U/L
Veh/CCI4 40 ± 4 327 ± 23
Veh/CCI4 (pair-fed) 17 ± 4 346 ± 26
VA/CCI4 6±2 3214* ±422
VA (75 mg/kg/day po) for 7 days or its vehicle followed
by CCI4 (0.2 ml/kg, ip). Mean ± SEM. *, significantly
different from Veh/CCI4 and Veh/CCI4 (pair-fed) groups
atp<0.05.
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Figure4. Mean bodyweightofmiceduring 7 days oforal
gavage with VA (75 mg/kg/d) (U) or its vehicle (5
ml/kg/day)(LI). The uppergraph demonstrates thetypical
weight loss due to VA treatment. The bottom graph
demonstrates that pair-fed controls lost an equal amount
of body weight. Each symbol is the mean ± SEM of 10
animals.
Table 4. Plasma ALT activities in male Swiss-Webster
mice pretreated with vitamin A or its vehicle combined
with paired-feeding to one group of vehicle-treated
animals.
Treatment Plasma ALT
group activities, U/L
Veh/CCI4 2236 ± 303
Veh/CCI4 (Pair-fed) 1413 ± 748
VA/CCI4 583* ± 144
VA (75 mg/kg/day, po) for 7 days or its vehicle fol-
lowed by CC14 (0.2 ml/kg, ip). Mean ± SEM. *, signifi-
cantly different from Veh/CCI4 and Veh/CCI4 (pair-fed)
groups at p<0.05.
40 ± 4 g during the course of the study.
Animals given daily doses ofVAgained only
6 ± 2 g during the study, while rats pair-fed
to the VA-treated rats only gained 17 ± 4 g
during treatment. Following dosing with
CC14 (0.2 ml/kg ip), VA-vehicle and pair-
fed rats had minimal elevations in plasma
ALT activities (approximately 325-350
U/L) while VA-pretreated rats had an
approximate 10-fold increase ofplasmaALT
activities (Table 3). Male Swiss-Webster
mice and their pair-fed vehicle controls both
lost approximately 25% of their body
weight over the 7 day VA dosing period
(Figure 4). However, when dosed with
CC14, VA-pretreated mice had an approxi-
mately 10-fold reduction in plasma ALT
activities as compared to both the pair-fed
and non-pair-fed CCI4 groups (Table 4).
Discussion
Vitamin A (retinol) is a widely used, over-
the-counter food supplement. Since it is fat
soluble and stored in the Ito cells of the
liver, many adults have increasing hepatic
stores of it through their lifetimes (12).
Studies over the last decade have shown
that VA can modulate elements of the
immune system, including macrophages.
Vitamin A and other retinoids (retinal and
retinoic acid) stimulate peritoneal
macrophages to increased phagocytosis and
interleukin production (2) and alveolar
macrophages to increased phagocytosis and
tumoricidal activity (8). Retinol, retinoic
acid, and retinyl palmitate have been
shown to increase the release ofsuperoxide
anion by phagocytic cells (13,14). In turn,
the secretory products of stimulated
peripheral blood monocytes and macro-
phages, including KC, have been shown to
be involved in hepatic injury following
exposure to hepatotoxicants (6,7, 15).
Superoxide dismutase (SOD) and catalase
(CAT) degrade superoxide anion and
hydrogen peroxide, respectively. Methyl
palmitate (MP) administration inhibits the
function of macrophages, including
Kupffer cells. In this laboratory, it has been
demonstrated that the administration of
SOD, CAT, or MP to rats alleviates the
VA-potentiated increase in CC)4-induced
hepatic damage (9). This suggests that the
potentiated liver damage is due, at least in
part, to reactive oxygen species released by
these phagocytic cells.
In the studies reported here, VA poten-
tiated CC14-induced hepatotoxicity to a
similar degree in male and female Sprague-
Dawley rats and in F-344 and athymic
nude rats. Vitamin A potentiation ofCC14
in athymic nude rats suggests that potentia-
tion can occur in the absence ofT-lympho-
cytes in this strain. Fischer-344 rats have
been shown to be more susceptible to pul-
monary oxidant-induced injury (16). Such
a strain difference may also be expressed in
the liver of F-344 rats since Smith et al.
(17) have shown them to be more suscepti-
ble to the hepatotoxic effects of the redox
cycling compound, diquat. In our VA
model, they responded in a similar manner
as both the Sprague-Dawley and athymic
nude rats, except that they required a lower
dose of CC14 to produce a comparable
degree ofliver injury.
Mice responded differently than rats in
this particular model of chemical induced
hepatotoxicity. As seen in the control ani-
mals in these studies, mice are more sus-
ceptible to CCI4-induced hepatotoxicity
than rats. Doses required to produce com-
parable elevations in serum ALT activities
were approximately one-tenth of those
required for rats. However, the most sur-
prising result was that pretreatment ofmice
with VA protected mice from CC14-
induced liver injury.
Mice exhibited considerable strain vari-
ability with respect to VA protection.
Balb/C and Swiss-Webster mice had an
approximately 4-fold protection; C3H/HeJ
(macrophage impaired), 10-fold protec-
tion; and athymic nude mice (T-lympho-
cyte deficient), 40-fold protection. In the
dose-response study in Swiss-Webster
mice, increasing doses of VA up to the
highest possible dose elicited increasing
protection from CCl4-induced liver injury.
This is in contrast to rats, which show
increasing potentiation of CC14 with
increasing doses of VA (10). The mecha-
nism(s) responsible for VA-associated pro-
tection of CC14-induced hepatotoxicity in
mice remain(s) to be elucidated. It is possi-
ble that differences in retinol metabolism
and tissue distribution between rats and
mice may explain, in part, the species dif-
ferences reported here. In rats, hepatic
retinol and retinyl palmitate concentrations
increased following VA treatment (10). We
are currently determining hepatic concen-
trations of retinol and retinyl palmitate in
mice following VA treatment at 75 mg/kg
for 7 days. In addition, studies of the
effects of VA on CC14 metabolism by
murine hepatocytes and on phagocytic cell
function are currently in progress.
It was observed that oral gavage with
VA resulted in weight loss in mice and a
reduction ofweight gain in rats. Since VA
can cause anorexia and weight loss in
humans, this finding was not unexpected
(18). Therefore, paired feeding studies
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were conducted in both species to deter-
mine the role offood intake in VA modu-
lation of CCI4-induced hepatotoxicity. In
both rats and mice, vehicle control animals,
pair-fed to VA animals, had reductions in
weight gain (rats) or decreases in body
weight (mice) similar to the VA animals.
However, when dosed with CC14, there was
no alteration of liver injury. Therefore, in
these studies, VA-associated weight loss or
decrease ofweight gain was not associated
with VA modulation ofCC14-induced liver
injury. Recent studies in our laboratory
indicate that VA administration to rats
may induce increased production oftumor
necrosis factor-ax(TNF-x, data not shown).
Since TNF-a (19) can result in weight
loss, this is a possible cause of the weight
loss or decreased weight gain (rats) that was
observed.
These studies demonstrate that large
doses ofVA can modulate the hepatotoxic
effects of subsequent administration of
CC14. The wide variability of responses
between species and among strains of the
same species (mice) make it difficult to pre-
dict the responses that will be seen in other
species, including humans. However,
retinoids have been reported to increase
macrophage and monocyte activity in peo-
ple. After consumption of excessive
amounts of VA some humans could be
exposed to other immunomodulators and
also to potentially toxic chemicals.
Therefore, it will be important to better
characterize how VA and other immuno-
modulators interact with the wide variety
of chemicals (drugs, environmental pollu-
tants, etc.) to which people are exposed and
to determine the mechanisms that explain
the differences observed in mice and rats
with respect to the effects ofVA on chemi-
cal induced hepatotoxicity. Such informa-
tion will assist in the extrapolation ofthese
results obtained in animals to humans.
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